不同分子分型乳腺癌脑转移癌临床特征及其生存分析

 目的 探讨不同分子分型乳腺癌脑转移的临床特征及其生存分析。方法 回顾性分析55例乳腺癌脑转移患者的临床资料,根据免疫组化结果分为luminal A型、luminal B型、HER-2过表达型、三阴型。分析4种亚型患者临床特征、治疗过程、确诊脑转移后生存情况。结果 4种亚型患者确诊脑转移癌后中位生存期分别为:10(0～49),8(1～51),7(0～19),8.5(0～21)个月,差异无统计学意义;中位总生存期、中位无病生存期及中位无脑转移生存期之间差异有统计学意义(P＜0.05),三阴型无病生存期最短,更早发生脑转移。结论 乳腺癌一旦确诊脑转移后,无论何种分子分型生存期均较短,尚无理想治疗手段。三阴型乳腺癌更易于早期发生脑转移。

Different molecular classification brain metastases from breast cancer clinical characteristics and survival analysis

Objective To study the different molecular typing and clinical features of brain metastases from breast cancer and survival analysis.Methods We retrospectively analyzed the clinical data of 55 patients with brain metastases from breast cancer, according to the Results of immunohistochemistry divided into luminal A, luminal B, human epidermal growth receptor-2(HER-2)＋,and triplenegative. We the analyzed their clinical characteristics, treatment process and survival after diagnosis of brain metastases in the four subtypes of patients.Results Four subtypes median survival after diagnosis of brain metastases in patients with cancer were: 10 (0-49), 8 (1-51), 7 (0-19), 8.5 (0 to 21) months, the difference was not significant, the median overall survival, median disease-free survival, and the median no brain metastasis survival difference were statistically significant between triple-negative disease-free survival shortest, brain metastasis occurred much earlier.Conclusions Once the diagnosis of brain metastases from breast cancer is confirmed, regardless of thmolecular typing survival period is short, there is no ideal treatment, brain metastases from triple-negative easier lead to early breast cancer.